BiotechTube
Home/Pipeline/ABBV-383

ABBV-383

Relapsed/Refractory Multiple Myeloma

Phase 1ActiveNCT03933735

Key Facts

Indication
Relapsed/Refractory Multiple Myeloma
Phase
Phase 1
Status
Active
Company
AbbVie

About AbbVie

AbbVie's mission is to discover and deliver transformative medicines that solve serious health issues. Its landmark achievement was building the world's top-selling drug, Humira, into a franchise while successfully navigating its patent expiry through a robust pipeline and strategic acquisitions like Allergan. The company's strategy hinges on sustained leadership in immunology, accelerated growth in oncology and neuroscience, and financial discipline to fuel high R&D investment and shareholder returns.

View full company profile

Therapeutic Areas

ImmunologyOncologyNeuroscienceEye CareVirology

Other Relapsed/Refractory Multiple Myeloma Drugs

DrugCompanyPhase
Aplidin (plitidepsin)PharmaMarApproved (Conditional - AU)
TECVAYLI + DARZALEX FASPROjohnson-and-johnson-innovative-medicineApproved
LinvoseltamabRegeneronPhase 3
Blenrep (belantamab mafodotin)GSKPhase III
CAR T-Cell Therapy ProgramDr. Reddy's LaboratoriesDevelopment
HDP-101Heidelberg PharmaPhase I/IIa
inobrodib + Pd (InoPd)CellCentricPhase 1/2
CT053CARsgen TherapeuticsPhase Ib/II
CT059CARsgen TherapeuticsPhase I
P-BCMA-ALLO1Poseida TherapeuticsPhase 1
P-BCMA-101Poseida TherapeuticsPhase 1/2
bri-cel (BAY 2413334)BayerPhase I